Analysis of correlation of DNAM-1 expression with AML subtypes according to WHO criteria revealed significantly lower DNAM-1 expression among AML cases classified as “AML with myelodysplasia-related changes” compared to “AML with recurrent genetic aberrations” and “AML, not otherwise specified” (p = 0.004 and p = 0.04 respectively) (Fig. 3I). This evidence concerns the gene CD226 and Myelodysplasia.